FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After ...

( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled ...